CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The pr...
Phase 1
Montréal, Quebec, Canada
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Montréal, Canada and 43 other locations
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Montreal, Canada and 46 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Montreal, Quebec, Canada and 54 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Montréal, Quebec, Canada and 209 other locations
, early-stage non-small cell lung cancer....
Phase 2
Montreal, Quebec, Canada and 94 other locations
combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...
Phase 1, Phase 2
Montréal, Quebec, Canada and 12 other locations
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...
Phase 3
Montreal, Quebec, Canada and 182 other locations
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...
Phase 3
Montreal, Quebec, Canada and 230 other locations
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer bef...
Phase 2
Montreal, Quebec, Canada and 9 other locations
Clinical trials
Research sites
Resources
Legal